Bepranemab not checked
UCB Biopharma SRL · UCB0107
FollowEvery change as it happens, and a Monday email
Trials
1 active
3 in total · 2 in the EU
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “UCB0107 (bepranemab) will be administered in a predefined dosage. Pharmaceutical Form: Solution for infusion Route of Administration: Intravenous”In the company’s words, NCT04658199 on ClinicalTrials.gov
- Tested for
- Progressive Supranuclear Palsy
- Main trialPhase 1
- “The purpose of the study is to assess the long-term safety and tolerability of UCB0107 in study participants with progressive supranuclear palsy (PSP).”In the company’s words, NCT04658199 on ClinicalTrials.gov
- Other names
- UCB0107
Other drugs for Progressive Supranuclear Palsy
- Antisense oligonucleotideNovartis · Phase 3
- ARO-MAPTArrowhead · Phase 1/2
Coming up1
- 13 Dec 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | 13 Dec 2027 | A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | |
| Phase 2Completed | 24 May 2024 | A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) | |
| Phase 1Completed | 17 Nov 2021 | A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026